We adapted existing methods for the same clinical setting, which was taken from a real PK/PD example, the development of the TGF‐β inhibitor LY2157299 in patients with glioma (Gueorguieva et al., 2014), where toxicity occurs after a high exposure to the drug. This evidence concerns the gene TGFB1 and central nervous system cancer.